Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (NASDAQ: APGE), sold a total of 5,500 shares of the company's common stock on April 1, 2026, generating about $466,619 in proceeds. The sales were carried out across multiple trades at prices between $84.31 and $85.89.
On the same date, Dambkowski exercised stock options to acquire 4,125 shares at an exercise price of $22.86, for an aggregate cost of $94,297. After these transactions, Dambkowski's direct holdings in Apogee total 208,398 shares.
The sales were made under a Rule 10b5-1 trading plan that Dambkowski adopted on September 22, 2025. At the time of the sale, the stock was trading around $84.34, according to InvestingPro data included in company and market reporting, which placed the price just below its 52-week high of $85.94. The company’s shares have risen substantially over recent periods, gaining 111% over the past six months and delivering a 161% return over the prior year.
Capital markets activity and recent offerings
Apogee has completed several public equity raises in the same general timeframe. The company sold 5.75 million common shares at $70.00 per share in a public offering, producing approximately $403 million in gross proceeds; that transaction included the full exercise of underwriters' options to purchase an additional 750,000 shares. In a related disclosure, the company recorded net proceeds of about $377.4 million from another public offering of common stock, an offering conducted under a shelf registration statement that has been effective since August 2024.
Separately, Apogee priced an additional stock offering at $350 million at $70 per share, which the company expected to close in March 2026.
Analyst coverage and clinical updates
On the analyst front, BTIG maintained a Buy rating on Apogee with a price target of $137. Mizuho increased its price target to $110 from $105 and kept an Outperform rating after the presentation of 52-week data for the company's investigational therapy zumilokibart in atopic dermatitis; Mizuho's adjustment included a 10% increase in its estimated probability of success for that indication.
Valuation context
InvestingPro analysis noted that Apogee's market capitalization stands at approximately $6.23 billion and that the stock appears overvalued relative to its assessed Fair Value, listing it among the platform's most overvalued stocks. Those valuation metrics are reported alongside the company's strong historical returns and recent capital raises.
Summary and implications
In aggregate, the insider sale and option exercise by the CMO, the substantial share price appreciation, recent equity offerings, and ongoing analyst activity form the recent public narrative for Apogee. The transactions were executed within an established trading plan, and the company's equity-financing actions have generated significant proceeds while coinciding with heightened market valuation metrics and analyst reassessments following clinical data presentations.
Key points
- Apogee CMO Carl Dambkowski sold 5,500 shares on April 1, 2026, for about $466,619 and exercised options to buy 4,125 shares at $22.86, spending $94,297; he now directly owns 208,398 shares.
- The sales occurred under a Rule 10b5-1 plan; the stock traded near $84.34 at the time and is close to its 52-week high of $85.94 after strong 6- and 12-month returns.
- The company has completed multiple public stock offerings that raised several hundred million dollars in gross and net proceeds, including a $403 million offering that included underwriter option exercise and a separately priced $350 million offering at $70 per share.
Risks and uncertainties
- Valuation risk: InvestingPro analysis flags Apogee as overvalued relative to its Fair Value, which may present valuation risk for equity holders and market participants.
- Dilution and financing risk: Multiple public offerings and the exercise of underwriter options have increased the company's outstanding shares and raised capital, which may impact per-share metrics for existing shareholders.
- Clinical and execution uncertainty: While analysts adjusted price targets and probabilities of success following 52-week data for zumilokibart, the company's future performance remains linked to clinical outcomes and execution around development programs.
These items intersect with sectors including biotechnology and healthcare, and they influence capital markets activity, particularly in equity financing and valuation assessment. The combination of insider transactions, elevated share prices, and substantial equity raises will likely remain focal points for investors and market watchers.